Optomed Plc announced on 9 August 2024 that it has conveyed 8,744 treasury shares to its Board of Directors as part of their annual remuneration, based on the decision of the Annual General Meeting 2024. Additionally, a total of 310,500 shares have been subscribed under the company’s stock option plans from 2015, 2017, 2018C, and 2019B, with treasury shares used for these subscriptions. As a result, the total number of treasury shares now stands at 34,729. Optomed is a Finnish medical technology company specializing in handheld fundus cameras and software aimed at diagnosing eye diseases like diabetic retinopathy, with operations in over 60 countries. For further information, contact CFO Sakari Knuutti at sakari.knuutti@optomed.com.

Optomed Plc announced a manager's transaction involving Seppo Mäkinen, a member of the board. On August 9, 2024, Mäkinen received 1,249 shares as part of a share-based incentive, with a unit price of 0.00 EUR. The transaction was reported as an initial notification.

Optomed Plc reported a manager's transaction on August 9, 2024, involving Ty Lee, a member of the Board. Lee received a share-based incentive consisting of 1,249 shares, with no associated cost. The transaction was classified as an initial notification.

On August 9, 2024, at 18:30 EET, Optomed Plc reported a manager's transaction involving Petri Salonen, a member of the Board/Deputy member. The transaction, which was an initial notification, involved the receipt of a share-based incentive. The transaction date was August 9, 2024, and the instrument type was a share with ISIN FI4000410881. The transaction involved 2499 shares at a unit price of 0.00 EUR, resulting in a volume-weighted average price of 0.00 EUR.

Optomed Plc reported a manager's transaction involving Laura Piila, a senior manager. The initial notification states that on August 7, 2024, Piila subscribed to 28,000 shares at a unit price of 3.50 EUR, linked to a stock option program. The aggregated transaction volume was 28,000 shares with a volume-weighted average price of 3.50 EUR.

Optomed Plc reported a manager's transaction involving Anna Tenstam, a member of the Board, on August 9, 2024. Tenstam received 1,249 shares as a share-based incentive, with a unit price of 0.00 EUR. The transaction is categorized as an initial notification.

Optomed Plc reported a manager's transaction involving Catherine Calarco, a member of the Board, on August 9, 2024. Calarco received 1,249 shares as a share-based incentive. The transaction had no unit price, resulting in a volume-weighted average price of 0.00 EUR.

Optomed Plc reported a manager's transaction on August 9, 2024, involving Reijo Tauriainen, a member of the board. The transaction, identified by reference number 7437009IVYWGEE4S7B77_20240809145959_58, involved the receipt of a share-based incentive. On the transaction date, 1249 shares with ISIN FI4000410881 were received, with a unit price of 0.00 EUR. The volume-weighted average price for the aggregated transactions was also 0.00 EUR.

Optomed Plc announced its financial reporting schedule for 2025. The Annual Report for 2024, including financial statements, the Board of Directors' report, corporate governance statement, and remuneration report, will be published by the week starting 24 February 2025. The Annual General Meeting is planned for 9 May 2025 in the Helsinki region, with the Board of Directors to convene the meeting later. Shareholders wishing to add items to the meeting agenda must notify the Board in writing by 13 March 2025. Optomed is a Finnish medical technology company specializing in handheld fundus cameras and software for diagnosing eye diseases, with operations in over 60 countries and 55 international patents. For further information, contact CFO Sakari Knuutti.